Cancer clinical trials in the region Île-de-France

787 currently recruiting clinical trials
Region Île-de-France
Phase 1 / Phase 2 Kidney cancer #NCT07293351
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Bristol-Myers Squibb
Phase 1 / Phase 2 Kidney cancer #NCT07293351
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Bristol-Myers Squibb
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06697197 #2024-516602-28-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Bristol-Myers Squibb
Phase 1 / Phase 2 Pancreas cancer #NCT06885034 #2025-520672-26-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT06885034 #2025-520672-26-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2 Chronic myeloid leukemia (CML) #NCT06163430 #2023-507677-18-00
Required disease stage
Chronic phase
Required genetic anomalies
BCR-ABL
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
ATP pocket inhibitor Allosteric inhibitor
Excluded previous treatments
Systemic Treatment-Naive
6 recruiting sites
Terns, Inc.
Phase 1 / Phase 2 Chronic myeloid leukemia (CML) #NCT06163430 #2023-507677-18-00
Required disease stage
Chronic phase
Required genetic anomalies
BCR-ABL
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
6 recruiting sites
Terns, Inc.
Phase 1 / Phase 2 Lung cancer #NCT05384626 #2024-514266-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2 Lung cancer #NCT05384626 #2024-514266-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer #NCT05384626 #2024-514266-39-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
AKT ATM BRAF BRCA 1/2 CDK12 CHEK 1/2 ESR FGFR HER2 HOXB13 KRAS G12C KRAS non G12C MET MSI/dMMR NRAS NTRK-1/2/3 PALB2 PIK3CA PTEN RET
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.